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ABSTRACT 1 
The insecticidal Cry toxins produced by Bacillus thuringiensis (Bt) are increasingly 2 
important in the biological control of insect pests of agriculture and vectors of human 3 
disease. Markets for Bt products and transgenic plants expressing their toxins are driven 4 
by their specificity, safety and the move away from chemical control agents. However, 5 
the high specificity of Cry toxins can also prove to be a limitation when there is no 6 
known Cry toxin active against a particular target. Novel activities can be discovered by 7 
screening natural Bt isolates or through the specific modification of regions of the Cry 8 
proteins responsible for recognising the receptors in target cells.  9 
Here we demonstrate the use of λ-phage displaying Cry1Aa13 toxin variants modified 10 
in domain II loop 2 (Crybodies) to select retargeted toxins. Through biopanning using 11 
gut tissue from larvae of the non-target insect Aedes aegypti, we isolated a number of 12 
phage for further testing. Two of the overexpressed Cry toxin variants showed 13 
significant activity against A. aegypti larvae while another induced mortality at the 14 
pupal stage. We present the first report of the use of phage display to identify novel 15 
activities toward insects from distant taxonomic Orders and establish this technology 16 
based on the use of Crybodies as a powerful tool for developing tailor-made insecticides 17 
against new target insects. 18 
 19 
SIGNIFICANCE STATEMENT 20 
Previous studies have shown changes in Cry toxin specificity through the construction 21 
of chimeric proteins or through localized mutagenesis.  There have also been numerous 22 
studies to construct and screen phage display systems for the screening of Cry toxin 23 
variants for novel activities but such studies report improvement of activity against the 24 
same target or activity toward insects closely related to the natural target. This work 25 
  3 
describes the success of a high-throughput molecular strategy for selecting Cry toxins 1 
active against a specific insect without the need for rational design or isolation of 2 
natural toxins.  The methodology presented here is based on phage display technology 3 
and allows the selection from a combinatorial library of Cry variants active toward a 4 
new target insect. This is the first report of phage display selection of a novel toxin 5 
active against a different insect order from the wild type toxin used to make the 6 
variants. This technology represents a promising strategy for obtaining tailor-made 7 
insecticides active against insects that are not susceptible to the currently known Cry 8 
toxins.  9 
 10 
INTRODUCTION 11 
Bacillus thuringiensis (Bt), is characterized by its ability to produce proteins with 12 
insecticidal activity. Toxins produced by Bt can form crystalline inclusions during 13 
sporulation 1 known as δ endotoxins (toxins Cry and Cyt) 2,3 or can secrete toxins during 14 
vegetative growth (VIP and Sip toxins) 4,5. Among these proteins, Cry toxins are the 15 
best characterized and exert their effect on the host by causing lysis of the midgut 16 
epithelial cells, which leads to gut paralysis, cessation of insect feeding, loss of 17 
membrane integrity, release of the cellular contents and eventual death 3,6-8.  18 
 19 
Currently, 302 holotypes of Cry toxins are described (http://www.btnomenclature.info/) 20 
as a result of a huge international effort to isolate and characterize novel Bt strains. Each 21 
of these toxins is reported to be active against a limited number of targets (mostly 22 
insects but also nematodes, molluscs and, in a few cases, human cancer cells 9) and this 23 
specificity is one of the most remarkable characteristics of Cry toxins. This specificity is 24 
a consequence of their complex and sophisticated mode of action, which, although not 25 
  4 
completely understood, is well-accepted to require the presence of receptors on the 1 
epithelial membrane of the target gut cells 2,10-12.  2 
 3 
Although Cry toxins may belong to a number of distinct structural families 9,13, the 4 
major group within Cry proteins is the so-called 3-domain toxins. The three-5 
dimensional structure of these toxins shows a remarkable similarity 14. Domain II, 6 
formed by three antiparallel beta-sheets arranged in a beta-prism form 15, has been 7 
associated with toxin specificity 12,16. Domain II is one of the most variable of the three 8 
domains, especially in three apical loops in this part of the molecule. These loops differ 9 
not only in sequence and conformation, but also in length. This variability, together 10 
with domain II’s similarity to the complementarity-determining region of 11 
immunoglobulins 15 led researchers to associate this domain with the role of receptor 12 
binding and hence with specificity. Exchange of the domain II regions among Cry 13 
toxins or modification of the sequences of the loops seems to be enough to alter the 14 
toxicity profile toward an insect 17-19.  15 
As mentioned above, the mechanism of action of 3-domain Cry toxins is not fully 16 
elucidated and currently three different models have been postulated for their function 17 
14,20. All proposed mechanisms involve binding to receptors present on the surface of 18 
target cells such as cadherin-like proteins, the amino peptidase N (APN), alkaline 19 
phosphatase (ALP), glycolipids 21, the glycoconjugate BTR-270 22, the P252 protein 23 20 
and the recently described transporter ABCC2 24,25. Although binding to the receptor is 21 
not the only requirement for toxicity, it is an essential requirement and it seems that 22 
natural evolution of Cry toxins has adapted them to recognize different proteins as 23 
receptors to be used in their mechanism of action.  24 
 25 
  5 
The toxic effect of Cry proteins has been commercially exploited for more than 70 years 1 
to control insect populations that have an impact on forestry, agriculture and health 2 
2,26,27 and toxin genes have also been used in plant transgenesis 28-34. The specificity of 3 
the Bt Cry toxins is a huge advantage; each toxin only affects a restricted number of 4 
insects species, leaving other, non-target organisms unaffected 35. Unfortunately, in 5 
many cases, there is no known toxin active against the insect of interest that can be used 6 
for its control. The traditional approach to search for new activities against a specific 7 
insect has been the isolation of hundreds of new Bt strains, and bioassaying their 8 
activity against the target insect to probe toxicity 36-38. This represents an extensive 9 
work programme and frequently no activity at all is found against the insect of interest.  10 
An alternative strategy to obtain Cry toxins with novel specificities is the modification 11 
of existing toxins through molecular techniques in order to increase the activity toward 12 
certain insects 39-41 and rationally redesign activity from one insect to another 17,19,41,42.  13 
 14 
Although these studies demonstrate that manipulation of toxins can render novel 15 
activities, this process is labour intensive and not very effective as many of the mutants 16 
rationally designed in this way may lack structural stability and function. Here, we 17 
demonstrate a high throughput screening methodology for the potential isolation of new 18 
toxins with novel activities against insect targets. The methodology is based on phage 19 
display technology, a potent molecular tool for in vitro selection of proteins with a 20 
specific binding profile. In this technique, a protein or a mutant library is fused to a 21 
phage protein so that it is displayed on the phage surface, ready to interact freely with 22 
other proteins. Several groups have described phage display of Bt toxins 43-49 but 23 
successful isolation of variants active toward taxonomically distant non-target insects 24 
has never been reported.   25 
  6 
Previously, we reported the display of a Cry1Ac toxin on the surface of a lambda phage 1 
that successfully interacted with its natural receptor 50. This was followed by a report of 2 
the construction of several Cry1Aa mutant libraries by replacing loops 1, 2 and 3 from 3 
the Domain II of the toxin with the hypervariable region contained at the 4 
complementary determinant region 3 (CDR-H3) of a human antibody library 51. The 5 
resulting cc2 library was displayed on the surface of a phage. The system combined the 6 
structure and scaffolding of the Cry toxins with the potential binding capability and 7 
specificity of a library of human antibodies (Crybodies). Here we present the screening 8 
of this library for the selection of toxins with novel binding profiles towards Aedes 9 
aegypti, an important vector of several flavivirus disease agents such as Dengue virus, 10 
Yellow fever virus and the currently emerging Zika virus. The selected Cry1Aa variant 11 
toxins were cloned in a heterologous expression system, overexpressed and bioassayed 12 
against A. aegypti, the non-canonical target insect chosen as a model.  Cry toxin variants 13 
selected in vitro using the phage display showed significant toxicity to A. aegypti. Thus, 14 
we demonstrate the proof of principle that in vitro evolution of a Cry toxin coupled with 15 
in vitro selection using phage display is a powerful tool for selecting novel toxins 16 
redirected against new-target insects across insect orders.  17 
 18 
RESULTS 19 
In vitro selection of phage with affinity to A. aegypti guts.  20 
The λcc2 phage display library, containing a diversity of 2.2 x 107 unique clones of Cry 21 
toxins with the domain II loop 2 of the lepidopteran active Cry1Aa13 toxin replaced by 22 
CDR-H3 sequences obtained from a human antibody library 52 was used in this study. A 23 
series of biopanning experiments was performed in order to select and enrich those 24 
phage from the library with enhanced affinity to targets present in the A. aegypti guts 25 
  7 
compared to the wild-type toxin. The pool of the phage obtained was considered as the 1 
sub-library 1. These phage were amplified and used for a new round of selection using 2 
fresh A. aegypti guts and this procedure was used in two further steps, each using the 3 
enriched phage from the previous round. The sub-library 4, resulting from the fourth 4 
round of selection, was used for further analysis. The number of phage recovered in 5 
each round of selection is shown in supplementary Table S1. As no significant increase 6 
of phage number in each round of selection was observed, further analysis was carried 7 
out in order to gain insight into any specific selection that may have occurred. To do 8 
this, the length of the loop 2 sequences present in a group of 15 randomly selected 9 
phage from sub-library 4 obtained by PCR with primers A2f and A2r, Supplementary 10 
Table 2S) was compared to the loop length from a group of 15 randomly selected clones 11 
from the original library λcc2 (Supplementary Fig. S1). The loop 2 size of phage in sub-12 
library 4 seemed to be less variable than the original library, probably indicating that a 13 
selective process had successfully occurred.  14 
 15 
Sequence analysis of loop 2 variants from sub-library 4.  16 
A2f-A2r PCR fragments obtained from a further 16 phage from sub-library 4 (different 17 
from the pool analysed in Fig. S1 and named from A1 to A16) were cloned in the 18 
pGEM-T vector and the resulting plasmids were sequenced and the amino acid 19 
sequence present at the loop 2 of the selected Cry mutants was determined (Fig. 1). The 20 
sequence analysis revealed that five of the phage (A3, A4, A5, A14 and A15) might 21 
display a truncated version of Cry toxins as a stop codon was found in their sequences 22 
(shown as “*”). The existence of these truncated proteins was probably due to errors in 23 
the assembly of the library or DNA amplification that rendered a shift in the reading 24 
frame as previously reported 51. Phage A3 and A4 showed the same sequence and the 25 
  8 
stop codon was found at the hypervariable region. Phage A14 and A15 show complex 1 
insertion patterns in which Gly-Ala-Arg- sequences introduced during library 2 
production, occur in the middle of the inserts rather than at the end. Phage A6 showed 3 
the same sequence as A7, corresponding to the wild type loop of Cry1Aa13. The rest of 4 
the phage A1, A2, A8, A9, A10, A11, A12, A13 and A16 (Fig. 1, black arrows) showed 5 
a sequence completely different to each other and different from the wild type with no 6 
stop codons introduced.  7 
The number of aa present at the hypervariable region in these 9 selected phage ranged 8 
from 13 to 19 aa. Compared to the original λcc2 library (7 to 25 aa reported by 51), the 9 
variability in sizes decreased significantly, probably due to the selection process.  10 
The 9 loop-variant mutants that did not contain stop codons (A1, A2, A8, A9, A10, 11 
A11, A12, A13 and A16), began with either Asp, Arg or Gly (after the Gly-Ala-Arg- 12 
sequence introduced during library production). Seven of the 9 ended with Cys (the 13 
other two ending with Trp), Tyr was the penultimate residue in 5 of these variants, 14 
preceded by Asp in 8 of the variants, preceded by an aromatic Phe (5 variants) or Tyr (2 15 
variants). Whether this reflects a positive selection for these residues during biopanning 16 
or a feature of the original library is not known at present.   17 
 18 
Reconstituting Crybodies from the selected phage. 19 
Phage in the library contain translational fusions between the active part of Cry1Aa13 20 
toxin (containing loop variants) and the phage coat protein gpD to allow toxin to be 21 
displayed on the phage surface 50,51. In order to assay the toxin variants selected with A. 22 
aegypti guts, loop variants were recloned into the pCP10-Δloop2 plasmid (following the 23 
strategy described in the Materials and Methods section and summarized in 24 
Supplementary Fig. S2). The resulting constructs were PCR screened with A2f and TD2 25 
  9 
primers (Supplementary Table S2) in order to select those clones with the correct 1 
orientation of the fragment. Plasmids pCP10-A1, pCP10-A2, pCP10-A5, pCP10-A8, 2 
pCP10-A9, pCP10-A10, pCP10-A11, pCP10-A12, pCP10-A13 and pCP10-A16 (named 3 
collectively as pCP10-Ai) were produced and contained mutant cry1Aa13 protoxin 4 
genes from phage A1, A2, A5, A8, A9, A10, A11, A12, A13 and A16 respectively.  5 
 6 
Expression profile of the cloned Crybodies.  7 
E. coli clones containing pCP10-Ai plasmids were grown in liquid media with IPTG 8 
and the accumulation of the mutant protoxins was analysed by SDS-PAGE (Fig. 2). In 9 
the pellet fraction of an E. coli pCP10 culture, a protein of 130 kDa corresponding the 10 
wild type Cry1Aa13 protoxin was observed (Fig. 2, lane 1). No such protein was 11 
detected in the clone bearing pCP10-Δloop2, as it contains a deleted version of the 12 
cry1Aa13 gene (Fig. 2, lane 2) and hence a truncated Cry protein is produced (that is 13 
probably unstable and does not accumulate). Clones pCP10-A8, -A10, -A11 and -A12 14 
showed a strong band of 130 kDa in size corresponding to Crybodies Cry1Aa13-A8, -15 
A10, -A11, and -A12 respectively. Clone pCP10-A1 (Fig. 2, lane 3) produced a minor 16 
band at this size.  The rest of the clones did not render any visible protoxin. 17 
Those clones with no visible accumulation of the full Cry protoxin were analysed by 18 
western blot (Supplementary Fig. S3) and expression of the full protoxin was only 19 
observed in the clone pCP10-A1, although at a very low level, consistent with the 20 
results from Coomassie staining. In the rest of the clones, smaller proteins were detected 21 
by immunoanalysis, indicating that protoxin was expressed but the protein was not 22 
stable enough to render the full Cry toxin, probably because of the loop replacement.  23 
 24 
Solubilisation and trypsin activation of Cry1Aa13-A8, -A10, -A11, and -A12 25 
  10 
Crybodies. 1 
The four Crybodies showing a good level of expression and stability (Cry1Aa13-A8, -2 
A10, -A11 and -A12) were solubilized and activated with trypsin under standard in vitro 3 
conditions 51. As shown in Fig. 3, all four Cry1Aa13-Ai Crybodies were successfully 4 
solubilized under the same conditions as the Cry1Aa13 wild type (Fig. 3, lane 1) and 5 
rendered a 130 kDa protein. Solubilized Cry1Aa13-A8, -A10, and -A12 Crybodies 6 
treated with trypsin produced a band around 65 kDa corresponding to the theoretical 7 
molecular weight of the active Cry toxin 52. However, Cry1Aa13-A11 showed a faint 8 
band around 65 kDa and more intense protein fragments of 37 and 28 kDa than the 9 
other mutants and the wild type toxin (probably as a result of digestion of the 65 kDa 10 
protein), indicating a lower stability of this mutant compared to the rest. As the stability 11 
of Cry1Aa13-A11 was compromised, this variant was not used in further experiments.  12 
 13 
Evaluating the toxicity of selected Crybodies against A. aegypti.  14 
The susceptibility of A. aegypti larvae to mutant toxins Cry1Aa13-A8, -A10 and -A12 15 
was determined. Fig. 4 shows the larval mortality obtained in the bioassays with each 16 
toxin. The mixture of Cry4Aa, Cry4Ba, Cry11Aa and Cyt1Aa obtained from Bti 17 
showed 100% mortality 24 h after the beginning of the bioassay as expected. The 18 
lepidopteran-active Cry1Aa13 toxin did not produce any mortality as A. aegypti is not 19 
susceptible to this protein. However, two mutant toxins, Cry1Aa13-A8 and -A12, 20 
showed a significant percentage of mortality after 120 h (around 90% mortality).  21 
The statistical analysis in a pair-wise comparison revealed significant differences 22 
between the toxicity of the proteins assayed. Each toxin was included in one of the 3 23 
significantly different groups; Cry1Aa13-wt and Cry1Aa13-A10 were included in group 24 
A, Cry1Aa13-A8 and -A12 in group B, and Bti was included in group C. The Kaplan-25 
  11 
Meier estimator (α = 0.05) was determined for Cry1Aa13-A8 and -A12 rendering 1 
values of 82 ± 0.87 h and 64.4 ± 0.88 h respectively. These results demonstrate that the 2 
two in vitro selected mutants Cry1Aa13-A8 and -A12 showed toxicity against A. 3 
aegypti, presumably mediated through affinity towards proteins present in the insect 4 
gut. LC50 values of these two variants were calculated by performing bioassays against 5 
4th instar larvae, using toxin concentrations ranging from 20 µg/ml to 1.25 µg/ml. Using 6 
Probit analysis it was estimated that LC50 values for Cry1Aa13-A8 and Cry1Aa13-A12 7 
were 10.4 µg/ml and 9.1 µg/ml respectively (Table 1). For comparative purposes, Table 8 
1 also details the LC50 of the naturally mosquitocidal toxins Cry4Aa, Cry4Ba, Cry11Aa 9 
and CytAa toxins reported in the bibliography 53,54,19,55,56,57,58 and reviewed by Otieno-10 
Ayayo et al 59. Taking the highest LC50 values for each natural toxin we can observe 11 
that Cry1Aa13-A8 showed a LC50 approximately 4.2 times higher than Cry4Aa, 10 12 
times higher than Cry4Ba and Cyt1Aa and 35 times higher than Cry11Aa. In the case of 13 
Cry1Aa13-A12, the LC50 was 3.75, 10, 31 and 9 times higher than Cry4Aa, Cry4Ba, 14 
Cry11Aa and Cyt1Aa respectively.  15 
 16 
Evaluating the toxicity of selected Crybodies against Bombyx mori.  17 
In order to determine how loop 2 replacement influenced the activity of the selected 18 
Crybodies against a canonical insect target of the wild type, parental toxin, variants 19 
Cry1Aa13-A8, Cry1Aa13-A10 and Cry1Aa13-A12 were bioassayed against B. mori 20 
together with the wild type toxin Cry1Aa13 and a mixture of non-active toxins (Cry4, 21 
Cry11 and Cyt) from Bti. The results showed (Table 2) that after 96 h the Cry1Aa13-22 
A10 variant (which is not active against A. aegypti larvae (Fig. 4)) showed 100% 23 
mortality in B. mori bioassays, as did the Cry1Aa13 wild-type toxin. In contrast, 24 
mortality produced by Cry1Aa13-A8 and Cry1Aa13-A12 variants was lower (45 ± 7% 25 
  12 
and 50 ± 14% respectively) than the wild-type, suggesting that loop 2 replacement 1 
negatively influenced in the activity against its natural lepidopteran target. As expected, 2 
low toxicity was recorded (20%) when Bti toxins were assayed against B. mori.  3 
 4 
Unexpected activities observed in the selected Crybodies. 5 
In addition to these results, another interesting observation was made in the bioassay 6 
performed with the Cry1Aa13-A10 mutant. Although the mortality of the larvae was 7 
0% at the end of the bioassay (Fig. 4) as described above, and all larvae became pupae, 8 
it was observed that all of these insects died within 24 h after pupation. This was an 9 
unexpected activity that is worth noting as, to our knowledge, pupal mortality as a result 10 
of exposure to Bt 3-domain Cry toxins has not been reported previously. This result also 11 
demonstrates that completely new activities can be obtained by using the phage display 12 
methodology that we have employed. Further investigations of this novel activity will 13 
be published separately.  14 
 15 
DISCUSSION 16 
It has been demonstrated extensively that the specificity of the 3-domain Cry 17 
toxins can be mediated by domain II of the protein, since this region has a role in toxin 18 
binding to natural receptors 60-64. Mutations within the loops of domain II can induce an 19 
increase of activity against target insects 39-41, and deletions, substitutions or 20 
replacements can even redirect toxicity toward related species 19,65.  In addition, in a 21 
program of rational redesign, the lepidopteran-active Cry1Aa was rendered toxic to the 22 
dipteran Culex pipiens by specific replacements in loops 1 and 2 of domain II 42.  As 23 
these studies involved rational redesign, similar experiments are only feasible when 24 
assessing the effects of chimeric proteins made from toxins with known activities and 25 
  13 
not for the development of toxicity against species that are not targets of currently 1 
available toxins.  These reports demonstrate that an important determinant of 3-domain 2 
Cry toxin specificity resides in the domain II loops and open the possibility of creating 3 
new toxin activities by manipulation of these loops. Construction of high-diversity Cry 4 
toxin mutant libraries through combinatorial techniques is relatively straightforward, the 5 
challenge in this artificial evolution is selecting and identifying those mutants from the 6 
library that may show interesting activity against a specific target.  Individually 7 
bioassaying each artificially-generated mutant from a combinatorial library to determine 8 
activity is impossible from a practical point of view and phage display offers a potential 9 
method for bio-panning such libraries to enrich for specific binding activities against 10 
any selected insect target. Of course, not all the variants selected would be likely to 11 
show activity, but as binding to insect guts is a requirement for Cry toxicity, binding 12 
was considered to be an appropriate filter to allow selection of a subset of variants for 13 
detailed analysis.  14 
The display of Cry toxins on the surface of phage has been attempted using 15 
several systems, which have sometimes encountered limitations.  In the first attempt to 16 
display a Cry toxin on the surface of a phage (Cry1Aa on M13 phage), the toxin was not 17 
properly displayed, resulting in deletions of the fusion protein 45.  Later, a complete 18 
Cry1Ac was displayed on the surface of the M13 phage, although the toxin did not 19 
show binding to its natural APN receptor in vitro, suggesting structural constraints of 20 
the displayed toxin 46.  Display systems based on λ and T7 phage proved to be more 21 
suitable alternatives for displaying Cry toxins, as they assemble in the E. coli cytoplasm 22 
and are released by cell lysis instead of secreting their components through the bacterial 23 
membrane as in M13 66. Cry1Ac was fused to the capsid protein gpD of λ phage and 24 
successfully displayed on the phage surface 50 with the Cry1Ac1::gpD fusion showing 25 
  14 
similar toxicity to the wild type and interacting with its natural receptors. Pacheco et al. 1 
(2006) reported the fusion of Cry1Ac toxin to the capsid protein 10B of T7 phage, 2 
successfully displaying a M. sexta active toxin able to bind M. sexta BBMV 44.  This T7 3 
display system was the basis for the construction of a mutant library containing 5x105 4 
variants bearing a 7-8 aa-long random sequence at loop 2 of the Cry1Aa1 toxin 47.  5 
Screening of this mutant library against Bombyx mori, a natural target of the parental 6 
Cry1Aa protein, identified a variant four times more potent than the wild type Cry1Aa1 7 
but screening of the library against other insects was not reported. Recently, Craveiro et 8 
al 2010 reported the selection of 4 variants of the lepidopteran-active Cry1Ia12 obtained 9 
by DNA shuffling and phage display technology. The Cry1Ia12 variants showed 10 
between 2 and 3 times more mortality than the wild type Cry1Ia12 toxin against the 11 
non-target lepidopteran sugarcane giant borer Telchin licus licus. This report showed 12 
that phage display can be used for selecting novel activities against new, taxonomically-13 
related targets, but the selection of variants active against more distinct orders of insects 14 
was not reported. Thus, nearly two decades after the first publication of Cry toxin phage 15 
display, the production through this technology of toxins retargeted toward 16 
taxonomically distant targets has not been described.   17 
The library used in our work, exploited our previous λ gpD-fusion phage display 18 
system 50 to express loop 2 domain II variants of Cry1Aa1351.  Compared to the display 19 
system developed by Ishikawa et al. (2007) 47, this λcc2 library contained a higher 20 
number of mutants (2.2x107 vs 5x105), the variants contained loops with a wider range 21 
of mutant sequences (7-25 aa vs 7-8 aa) and our library was constructed by replacing 22 
loop 2 by an antibody CDR-H3 library, which may prove an inherently better source of 23 
binding motifs than artificially-generated random sequences. All these factors may 24 
  15 
underlie the ability of the system developed in the present work to provide the 1 
breakthrough to yield variants with completely novel activities.  2 
After 4 cycles of biopanning with A. aegypti guts, the derived pool of phage 3 
showed a hypervariable region in loop 2 ranging from 13 to 19 aa as opposed to the 7-4 
25 aa present in the original library51, a reduction in diversity consistent with a 5 
selection/enrichment process.  The analysis of the sequences of the selected phage 6 
showed that some displayed a truncated version of the mutant toxin, probably due to 7 
assembly problems in the construction of the λcc2 library.  The truncated Cry toxins are 8 
not expressed beyond domain II loop 2 and it is not clear whether their presence in the 9 
enriched phage pool is due to unexpected specific binding or whether they are part of 10 
the inevitable background binding.  The presence of such phage in the library and their 11 
retention represents a decrease in the recovery efficiency of the system that we are 12 
currently working to circumvent.  13 
 Analysis of full-length Cry protoxins, reconstituted from selected phage showed 14 
that not all the Cry mutants retained during enrichment were suitable for heterologous 15 
over-expression. Attempts to express mutant toxins such as Cry1Aa13-A1, -A2, -A5, -16 
A9, -A13, and -A16 resulted in no significant accumulation of the protoxin.  As all 17 
toxins were expressed from the same promoter (Ptac promoter), the failure to accumulate 18 
these toxins is most likely due to the low stability of the mutants.  This was confirmed 19 
in western blots, which detected small fragments of Cry toxins, implying that these 20 
mutant proteins were expressed but were subject to degradation.  The lack of stability 21 
can only be attributed to the change in the sequence of the loop 2 as the rest of the 22 
molecule was unchanged.  Low stability and increased proteolytic sensitivity observed 23 
for some mutants may arise from conformational changes elsewhere in the protein, 24 
induced in the molecule by the novel loop 2 variants (Supplementary Fig. S4). 25 
  16 
Alternatively, the introduction of random sequences may provide direct proteolytic 1 
target sites within loop 2.  Mutants Cry1Aa13-A9, -A13 and -A16, which are 2 
particularly unstable and the more stable Cry1Aa13-A11 mutant may illustrate 3 
proteolytic sensitivity at the mutated loop as they contain Lys and or Arg residues in 4 
this region that would introduce potential susceptibility to cleavage by trypsin-like 5 
enzymes.  Cry1Aa13-A11 is stable enough to be produced in the pellet fraction of 6 
recombinant E. coli but can be subsequently degraded by trypsin digestion, possibly at 7 
the Arg residue in its loop 2.  In contrast, while the stable mutant Cry1Aa13-A10 also 8 
has an Arg residue in the loop, it appears to be activated normally by trypsin.  However, 9 
the Arg in this variant is followed by a Pro residue and endoproteolytic cleavage N-10 
terminal to a Pro residue is very unusual in nature 67. Three mutants, Cry1Aa13-A8, -11 
A10, and -A12 showed high levels of expression and normal trypsin-activation profiles, 12 
so they were selected for bioassays against A. aegypti.  Cry1Aa13-A10 showed an 13 
unexpected activity, with no apparent effect on A. aegypti larvae but exhibiting delayed 14 
mortality at the pupal stage. Blocking the development of adults through pupal 15 
mortality may represent an important new means to disrupt disease transmission.  The 16 
activity of this mutant needs to be characterized further but this variant demonstrates the 17 
capacity of the strategy developed here to expand selection of toxins beyond the larval 18 
stage of the insect, and widen the possibility of targeting other stages; a feature that 19 
could represent an advantage in the control of many natural insect populations.   20 
Variants Cry1Aa13-A8 and -A12 were able to produce a high mortality in larval 21 
populations (90%). Although the amount of toxin used in the bioassays was quite high 22 
(20 µg/ml) the wild type Cry1Aa13 showed no toxicity at this concentration, (LC50 for 23 
the Cry1Aa13 is higher than 100 µg/ml according our experience). The mutant activity 24 
is clearly lower than the toxicity of Bti crystals used as the positive control, but these 25 
  17 
contain at least three different Cry toxins (Cry4Aa, Cry4Ba, and Cry11Aa) and one Cyt 1 
protein (Cyt1Aa) with possible production of Cyt2Ba and Cry1Ca and Cry10Aa 68,69  2 
active against A. aegypti with different toxicity levels 70,71. The activity of each 3 
individual toxin produced by Bti against A. aegypti has been determined by several 4 
research groups and compiled by Otieno-Ayayo et al. 59. These authors found a high 5 
variability of the LC50 reported in the literature for Cry4Aa (0.56-2.39 µg/ml), Cry4Ba 6 
(0.06-0.94 µg/ml), Cry11Aa (0.01-0.28 µg/ml) and Cyt1Aa (0.8-1.0 µg/ml) toxins 7 
against A. aegypti as a consequence of factors such as where the toxins are produced, 8 
how the toxins are purified and processed or the conditions of the bioassays. Although 9 
comparison of the LC50 obtained in different bioassays is not completely accurate, it 10 
provides an opportunity to demonstrate that the activity of the Cry1Aa13 variants 11 
obtained by phage display may be within an order of magnitude of the toxicity of toxins 12 
naturally active against the model insect. If we compare the highest reported LC50 value 13 
for each individual Bti toxin with the Cry1Aa13-A12 variant for example, we can 14 
roughly estimate that toxicity of the latter is 3.79-32 times lower than individual 15 
mosquitocidal toxins. Bti toxins have evolved to target nematoceran Diptera for millions 16 
of years, allowing evolutionary optimisation of the toxins for their target. Thus, we have 17 
demonstrated significant activity for Cry1Aa13-A8 and Cry1Aa13-A12 against A. 18 
aegypti (within one order of magnitude of the natural mosquitocidal toxins). This is a 19 
good level of toxicity for proof of principle for our system, considering that variations 20 
were introduced without rational design, in only a single loop and the derived toxins 21 
have not undergone further optimisation. The level of toxicity shown by variants 22 
Cry1Aa13-A8 and Cry1Aa13-A12 was similar to the activity gained in C. pipiens in the 23 
rational design previously reported by Liu and Dean, (2006). The mutant 1AaMosq, 24 
containing a Loop 1 substitution (311RG312 by YQDL) and a Loop 2 deletion 25 
  18 
(365LYRRIIL371) plus a substitution (376NNQ378 was replaced by a G) showed a LC50 1 
value for 2nd instar larvae of 45.73 µg/ml while LC50 for A. aegypti 4
th instar larvae for 2 
Cry1Aa13-A8 and Cry1Aa13-A12 was 10.4 and 9.1 µg/ml respectively. In the report of 3 
Liu and Dean 42, loop 2 in the 1AaMosq was shortened to mimic the mosquito-active 4 
Cry4B loop 2. In contrast, our selected variants Cry1Aa13-A8 and Cry1Aa13-A12 5 
showed a loop length similar to the Cry1Aa13 parental toxin (13 and 18 aa respectively) 6 
but very different in sequence. In addition, the loop2 sequences present in mosquito-7 
active Cry1Aa13 variants have no significant similarity to loop 2 regions from other 3-8 
Domain Cry toxins, including the mosquitocidal toxins Cry4Aa, Cry4Ba and Cry11.  9 
A correlation is observed in our results between the development of toxicity of 10 
Cry1Aa13-A8 and Cry1Aa13-A12 toward A. aegypti concomitant with decreases in 11 
toxicity toward B. mori. It is interesting to note that Cry1Aa13-A10, which did not 12 
show any activity against A. aegypti larvae, retained its activity against B. mori. It will 13 
be interesting to investigate the molecular targets of these new variant toxins to 14 
determine whether they are associating with known receptor types (eg cadherins, amino 15 
peptidases, alkaline phosphatases) or new classes of binding ligands. Binding studies of 16 
the three variants with A. aegypti and B. mori BBMVs are in progress. 17 
It should be noted that the two larvicidal and one pupicidal variants described 18 
were identified from a detailed analysis initiated from only 16 randomly selected phage 19 
from our biopanning, further refined to just 9 candidates after initial sequence analysis.  20 
This represents an excellent level of efficiency and clearly incentivises the screening of 21 
further variants.  In the longer term, efficiency may be enhanced by improving library 22 
quality (with fewer truncated variants) and may be aided by the introduction of an 23 
increased number of biopanning rounds prior to clone testing. Increasing the biopanning 24 
stringency between rounds would be desirable but there are problems with changing 25 
  19 
stringency when there is little or no control over the number or concentration of target 1 
molecules 72 (as in our screening with no defined target in tissue samples and the ability 2 
of phage to select the targets to which they might bind).  Further development of higher 3 
toxicity variants may also be aided by the separate screening of libraries with diversity 4 
in variable loops ∝8, 1 and 3 with the subsequent combinatorial mixing (by simple 5 
combination or, for example, through DNA shuffling techniques) of mutants showing 6 
activity.  7 
Very recently, a report on Cry toxin evolution using PACE (phage-assisted 8 
continuous evolution) has been described 73. In this paper authors designed a complex 9 
and outstanding in vitro evolution system that enables novel Cry variants to be obtained 10 
that are active against resistant insects. This work, like ours, supports the idea that in 11 
vitro evolution is the strongest tool for obtaining tailor-made insecticides that the 12 
market demands. However, the evolved toxins obtained by PACE showed activity 13 
against closely-related insects species and maintained a similar insecticidal spectrum as 14 
the parental Bt toxin. As a result, there may be only relatively minor changes in receptor 15 
molecules to which toxins must be adapted. In contrast, we have demonstrated that 16 
Crybody phage display can go even further to obtain novel variant with activities 17 
against distinct orders of insects. The work presented here has provided the proof of 18 
principle that phage display, our library and the selection strategy developed are suitable 19 
molecular approaches for selecting toxins with activity redirected to new target insects 20 
even across taxonomic orders. This technology can now be exploited to tackle new 21 
pests for which no Bt toxins are currently available and also as a strategy to overcome 22 
resistance that has arisen in the field.  23 
 24 
 25 
  20 
MATERIALS AND METHODS 1 
Bacterial and phage strains. Escherichia coli strain DH5α was used for cloning and 2 
expression studies. E. coli strain Y1088 was used for phage amplification. E. coli strain 3 
BLR containing the pCP10 plasmid was used for obtaining Cry1Aa13 toxin 52. B. 4 
thuringiensis var israelensis 4Q5 was used to obtain Cry4Aa, Cry4Ba, Cry11Aa and 5 
Cyt1Aa toxins. All phage used were derived from the λEMBL3 vector (Promega) 74. 6 
The λEMBL3-pTI11 contained the plasmid pTI11 as test insert plasmid supplied in the 7 
Promega kit and used for controlling packaging efficiency. λCP2 phage displayed the 8 
wild type Cry1Aa13 toxin and the λcc2 mutant library contained approximately 107 9 
unique variants of Cry toxins (kindly provided by Prof. D. J. Ellar from the University 10 
of Cambridge) 52. 11 
 12 
Phage amplification and concentration. E. coli Y1088 was grown overnight at 37ºC 13 
(240 rpm) in 5 ml of NZCYM medium (5 g/l NaCl, 2 g/l MgSO4·7H2O, 5 g/l yeast 14 
extract, 10 g/l casein enzymatic hydrolysate, 1 g/l casein acid hydrolysate) 15 
supplemented with ampicillin (100 µg/ml). After determining the A600 nm of the culture, 16 
an appropriate volume, containing 1010 cells (assuming that 1 U of A600 nm corresponds 17 
to 109 cells/ml) was centrifuged and the pellet resuspended in 300 µl of SM (100 mM 18 
NaCl, 10 mM MgSO4, 50 mM Tris-HCl, 0.01% gelatin, pH 7.5), and mixed with a 19 
phage suspension containing 107-108 pfu. After 20 min incubation at 37ºC the mixture 20 
was added to 50 ml of fresh NZCYM and incubated (37ºC, 150 rpm) in a rotary shaker 21 
until lysis of the culture was completed (A600 nm 0.1-0.2). Then, 1 ml of chloroform was 22 
added, incubated for a further 20 min and treated with pancreatic DNase (Sigma) and 23 
RNase (1 µg/ml, Sigma) at RT for 30 min. Solid NaCl was added to a final 24 
concentration of 1 M and incubated on ice for 1 h before being centrifuged (12000 x g) 25 
  21 
for 20 min. The supernatant was mixed with PEG 8000 (10% (w/v) final concentration), 1 
incubated for 1 h on ice and centrifuged at 12000 x g for 20 min and the pellet 2 
resuspended in 800 µl of SM. An equal volume of chloroform was added and the 3 
mixture vortexed for 30 seconds. The upper aqueous phase containing the phage 4 
suspension was recovered and stored at 4ºC until use. 5 
 6 
Phage quantification and phage propagation on plates. E. coli Y1088 was cultured 7 
in 50 ml of LB (plus maltose 0.2% (w/v), 10 mM MgSO4 and ampicillin 100 µg/ml) at 8 
37ºC and 240 rpm until a A600 nm of 0.5-0.6. Culture was pelleted, resuspended in 25 ml 9 
of 10 mM MgSO4 and kept at 4ºC and used within a month when needed. For phage 10 
titration, 200 µl of this E. coli Y1088 suspension was mixed with 200 µl of a phage 11 
suspension, incubated for 20 min at 37ºC, mixed with 3-4 ml of molten top agarose 12 
(50ºC) (per liter: 10 g tryptone, 5 g yeast extract, 10 g NaCl, 6 g agarose) and poured 13 
onto a LB agar plate. Plates were incubated at 37ºC overnight for plaque counting. 14 
Plaques were propagated and amplified in solid media with the use of a sterile toothpick 15 
and a LB agar plate containing top agarose with E. coli Y1088.  16 
 17 
Aedes aegypti rearing and management. A. aegypti eggs were incubated in a plastic 18 
container with dechlorinated water and ground artificial diet (commercial dry cat food) 19 
at 25ºC ± 2ºC, 70% humidity and a photoperiod (12 h light /12 h darkness). Eggs 20 
hatched within two days. Fourth instar larvae were used for biopanning experiments and 21 
bioassays. 22 
 23 
In vitro biopanning. Biopanning was performed with ten guts extracted from Virkon®-24 
treated 4th instar A. aegypti larvae. Guts were obtained by pulling from the neck and the 25 
  22 
anal segment of the larva with 2 ultra fine point tweezers. Guts were placed in cold PBS 1 
for peritrophic membrane removal and then placed in 200 µl of SM buffer 2 
supplemented with protease inhibitors (complete mini protease inhibitor cocktail, 3 
Roche) in an Eppendorf tube. Insect tissue was disrupted with a micropestle (Sigma) 4 
and mixed with the appropriate volume of the phage suspension of λEMBL3-pTI11, 5 
λCP2 or λcc2 to give a final concentration of 109 PFU/ml. Phage and insect gut 6 
homogenates were incubated for 30 min at RT and then centrifuged at 16000 x g for 10 7 
min. Pellets were resuspended in 500 µl of washing buffer (1.5 M NaCl, 0.1% Tween 8 
and protease inhibitor) and centrifuged again under the same conditions. Washing was 9 
repeated 5 more times and the final pellet was resuspended in 200 µl of SM buffer. 10 
Phage attached to material present in the pellet fractions were recovered by incubation 11 
(20 min at 37ºC) with 200 µl of E. coli Y1088 prepared as indicated above. The mixture 12 
was placed in 50 ml of NZCYM medium for phage amplification. When the number of 13 
the selected phage (sub-library) reached more than 1010 PFU/ml, a new round of 14 
biopanning was started to enrich phage able to bind to the gut (and deplete the relative 15 
proportion of phage present due to non-specific binding). Four rounds of selection were 16 
performed in total and phage present in the final sub-library were kept for further 17 
experiments and analysis.  18 
 19 
Loop 2 cloning and sequence determination. Loop 2 mutants present in selected 20 
phage were PCR amplified using A2f-A2r primers (Supplementary Table S2), purified 21 
and ligated into pGEM®-T vector (Promega) following the manufacturer’s instructions. 22 
Plasmids were sequenced using primer M13f.  23 
 24 
Constructing pCP10-Δ loop2 plasmid. To facilitate recovery and overexpression of 25 
  23 
protoxin forms of cry gene variants identified through phage screening, we constructed 1 
the plasmid pCP10-Δloop2 containing a 500 bp deletion in the cry1Aa13 gene that 2 
included the region encoding loop 2 of the protein. This provided a toxin scaffold ready 3 
for the insertion of any of the loop 2 mutants from the selected phage and avoided the 4 
relatively inefficient amplification and cloning of ~ 2 kb encoding the entire toxin 5 
region. SalI restriction sites were introduced to facilitate the cloning strategy as the 6 
introduction of this restriction site did not change the aa composition of the protein. The 7 
pCP10-Δloop2 plasmid (Fig. S1) was constructed by PCR (95ºC/5 min, 30 cycles at 8 
95ºC/45 sec, 60ºC/45 sec, 72ºC/7 min) using pCP10 plasmid as template and the 9 
divergent primers TD12 and TD13 (Table S2). The PCR amplicon was purified 10 
(Qiagen), digested with SalI (NEB), heated for enzyme inactivation and self-ligated 11 
with T4 DNA ligase (Promega). The circularized plasmid produced, pCP10-Δloop2, 12 
was then ready to accept any mutant loop 2 in the newly introduced SalI site. 13 
 14 
Construction of new variant toxin plasmids. The region that includes the loop 2 of 15 
domain II of the different selected phage was amplified using the primers TD10 and 16 
TD11 (Table S2) by PCR (1 cycle at 95ºC/5 min, 30 cycles at 95ºC/30 sec, 63ºC/30 sec, 17 
72ºC/30 sec and a final extension at 72ºC/5 min). PCR fragments were purified, SalI 18 
digested and ligated to the SalI-dephosphorylated pCP10-Δloop2 for transformation of 19 
E. coli DH5α. Successful constructs were screened by colony PCR using A2f and TD2 20 
primers (Table S2). 21 
 22 
Protein expression, solubilisation and trypsin activation conditions. Each toxin 23 
variant was cultured in 50 ml of LB (plus 1 mM IPTG and 100 µg/ml ampicillin) at 24 
37ºC, 240 rpm for 16 h. The culture was pelleted and resuspended in 1 ml of lysis buffer 25 
  24 
(50 mM Tris HCl pH 8, 500 mM NaCl, 10 mM EDTA, 5 mM β-mercaptoethanol, 0.35 1 
mg/ml lysozyme and 5% v/v triton) and incubated for 30 min at RT. Then, 10 µg/ml 2 
DNase (Sigma), 10 µg/ml RNase (Sigma) and 6 mM MgCl2 were added and incubated 3 
for a further 20 min. The cell suspension was sonicated on ice (Sonifier® SLP) for 6 4 
min with cycles (10 s on/10 s off) at full power. The homogenate was centrifuged at 5 
12000 x g for 20 min and the supernatant discarded. The pellets were resuspended in 6 
500 µl of 50 mM Na2CO3 pH 9.6 and 10 mM DTT, incubated for 1 h at 37ºC, 7 
centrifuged and supernatant saved. For activation, solubilized protein was digested with 8 
TPCK-treated trypsin from bovine pancreas (Sigma) at a ratio of 1:1 (w/w) at 37ºC for 1 9 
h. Protein samples were analysed by SDS-PAGE (12 %, Coomassie blue stained). Total 10 
protein content was determined by the Bradford method. Single protein content was 11 
estimated using a ChemiDoc equipment (Bio-Rad) on SDS-PAGE gels using BSA as 12 
standards.    13 
A. aegypti bioassays. Ten early fourth-instar A. aegypti larvae were placed in 10 ml 14 
dechlorinated water containing 20 µg/ml of each Cry1Aa13 selected mutant, the 15 
lepidopteran active Cry1Aa13-wt or a mixture of solubilised Cry4Aa, Cry4Ba, Cry11Aa 16 
and Cyt1Aa, obtained from a sporulated culture of B. thuringiensis subsp. israelensis 17 
strain 4Q5 (grown in T3 medium for 72 h, centrifuged at 4000 g for 20 min, and 18 
solubilized in Na2CO3 50 mM pH 9.6 and DTT 10 mM for 1 h at 37ºC). Apart from 19 
solubilized toxins, ground dry cat food was added in each assay. Assays were performed 20 
at 26 ºC. Mortality was analyzed every 24 h until all larvae died or pupated. Each toxin 21 
was assayed in duplicate and the bioassays were performed twice. The results were 22 
analyzed statistically using the XLSTAT program. 23 
For LC50 determination, bioassays were performed under the same conditions using 5 24 
concentrations (20, 10, 5, 2.5 and 1.25 µg/ml) of Cry1Aa13-A8 and Cry1Aa13-A12. 25 
  25 
Each toxin was bioassayed in duplicate and each assay repeated twice. Mortality was 1 
recorded after 6 days and LC50 values were calculated by Probit analysis 
75.   2 
B. mori bioassays. Toxicity of Cry variants against B. mori was determined using diet 3 
contamination bioassays in neonate larvae. A mulberry leaf cut in a square shape (size 4 
3x3 cm) was placed in a plastic Petri dish. On the leaf, 100 µl of a toxin solution 5 
containing 3.2 µg/ml of toxin was spread with the use of a sterile L-shaped spreader, 6 
rendering a toxin concentration of 36 ng of toxin per cm2 of diet,  (3 times higher than 7 
the LC50 for Cry1Aa reported in the bibliography against B. mori 
25. Apart from the 8 
toxin variants selected by phage display, Cry1Aa13 and a mixture of Cry toxins 9 
obtained from Bti were used as positive and negative controls respectively. Ten 10 
neonates of B. mori were placed in each Petri dish with the help of a fine brush. Plates 11 
were kept at 25ºC and 50% humidity in an insect room and mortality was recorded daily 12 
for 96 h. 13 
 14 
Modelling method. The structures of Cry1Aa13 variants were modelled on the 15 
structure of Cry1Aa 76 submitted under accession number 1CIY in the pdb using the 16 
Swiss model program 77.  The template was believed to be valid due to the fact that it 17 
contains only 2 amino acid changes compared to the Cry1Aa13 protein.   18 
 19 
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FIGURE LEGENDS 22 
Figure 1: Alignment of the loop 2 sequences present in the in vitro selected Cry phage 23 
and the wild type Cry1Aa13 toxin. 24 
  36 
Arrowheads indicate novel loop variants in sequences that do not contain premature 1 
stop codons. Bold letters represent the predicted hypervariable region present in each 2 
mutant after loop 2 replacement. 3 
 4 
Figure 2: Production of variant protoxins. 5 
Coomassie blue stained 12 % acrylamide gel showing the insoluble fractions of IPTG 6 
induced cultures of E. coli with pCP10 (lane wt) as positive control, and pCP10-Δ loop2 7 
(lane D) as negative control. Clones bearing plasmids pCP10-A1 (lane A1), pCP10-A2 8 
(lane A2), pCP10-A5 (lane A5), pCP10-A13 (lane A13), pCP10-A16 (lane A16), and 9 
pCP10-A9 (lane A9), did not show over-expression of the Cry protoxin. Clones bearing 10 
plasmids pCP10-A8 (lane A8), pCP10-A10 (lane A10), pCP10-A11 (lane A11) and 11 
pCP10-A12 (lane A12) showed a strong Cry protoxin production similar to the wild 12 
type Cry protoxin. 13 
 14 
Figure 3: Solubilization and trypsin treatment of protoxin variants.  15 
Coomassie blue stained 12% acrylamide gel showing solubilized protein treated (+) and 16 
untreated (-) with trypsin. Cry1Aa13 wild type was used as positive control for 17 
solubilisation (lane wt -) and trypsin activation (lane wt +). Lanes A8, A10, A11 and 18 
A12 show the solubilized Cry1Aa13-A8, Cry1Aa13-A10, Cry1Aa13-A11 and 19 
Cry1Aa13-A12 respectively. Trypsin-treated toxins exhibited a protein of 65 kDa 20 
corresponding to the core of the toxin or activated toxin. Cry1Aa13-A11 showed the 21 
same band but less intense than the rest of the mutants. Arrows A and B indicate the 22 
molecular weight of the approximately 37 kDa and 28 kDa fragments observed during 23 
trypsin digestion.  24 
 25 
  37 
Figure 4: Percentage mortality of A. aegypti larvae on treatment with soluble toxins.  1 
Results obtained with Cry1Aa13-wt toxin (dark blue), Cry1Aa13-A8 (red), Cry1Aa13-2 
A10 (green) and Cry1Aa13-A12 (purple) and Bti (cyan) treatments.  3 
 4 
Legends for supplementary data: 5 
 6 
Figure S1: Phage library insert size variation.  7 
Electrophoresis in 2% agarose gels of PCR fragments obtained with A2f and A2r 8 
primers showing the size of the loop 2 present in the original λcc2 library (Panel A) and 9 
in the in vitro selected phage (Panel B). Lane E shows the negative control (λEMBL3-10 
pTI11) and lane C the positive control (λCP2). 11 
 12 
Figure S2: pCP10-Dloop2 construction and cloning strategy for the recovery of the 13 
mutant Cry toxins displayed in the selected phage. 14 
 15 
Figure S3: Immunoblot analysis of protoxin expression.  16 
Toxin bands were revealed using a polyclonal anti-Cry1Ab antibody (Abcam). Plasmid 17 
pCP10-A1 (lane A1) showed the expression of a 130 kDa protein with the same size as 18 
the positive control pCP10 (lane wt) that expresses the Cry1Aa13 protoxin. Plasmids 19 
pCP10-A2 (lane A2), pCP10-A5 (lane A5), pCP10-A13 (lane A13) and pCP10-A16 20 
(lane A16) showed a similar protein profile as the negative control pCP10-Δloop2 (lane 21 
D). 22 
 23 
  38 
Figure S4. Modelled structure of mutant loops. The modelled structures of domain II, 1 
loop 2 for mutants Cry1Aa13-A8 (cyan), Cry1Aa13-A10 (magenta) and Cry1Aa13-A12 2 
(pink) are overlaid on the modelled wild-type Cry1Aa13 (green) loop. 3 
 4 
 5 
 6 
TABLES 7 
Table 1: LC50 values of Cry1Aa13 variants obtained in A. aegypti bioassays and 8 
comparison with the reported in the literature for individual toxins from Bti.   9 
 10 
 11 
Toxin LC50
a
 (µg/ml) SD Source
b
 
Cry1Aa13-A8 10.4 (8.358-12.453) 1.0 This study 
Cry1Aa13-A12 9.1 (8.094-10.021)  0.5 This study 
Cry1Aa13-A10 >> 20 a ND This study 
Cry1Aa13 >> 20 a ND This study 
Toxin LC50
c
 (µg/ml)                  Source
b
 
Cry4Aa 0.56 Poncet et al. 53 
Boonserm et al. 54 
Abdullah et al. 19 
Angsuthanasombat et al. 55  
Revina et al. 56 
Poncet et al. 53 
Thiery et al. 57 
Juarez-Perez et al. 58 
 2.39 
Cry4Ba 0.06 
 0.94 
Cry11Aa 0.011 
 0.28 
Cyt1Aa 0.88 
1.00 
aMean lethal concentration (LC50) was estimated by Probit analysis. 95% confidence limits are given in 12 
parentheses when known. ND = not determined 13 
bSource of the LC50 values presented in the table, determined in this study or taken from literature and 14 
reviewed by Otieno-Ayayo et al 59. 15 
c LC50 values (the lowest and the highest) reported in the literature. 16 
 17 
 18 
 19 
Table 2: B. mori mortality recorded after 96 h in contaminated mulberry leaf-20 
bioassays.  21 
 22 
 23 
Toxin (36 ng/cm
2
) 
  39 
  Cry4 and Cry 11 
from Bti 
Cry1Aa13 
(wt) 
Cry1Aa13-A8 Cry1Aa13-A10 Cry1Aa13-A12 
% Mortality ± 
SD  
20 ± 10 100 ± 0 45 ± 7 100 ± 0 50 ± 14 
 1 
 2 
 3 
Figure 1 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
Figure 2  12 
 13 
Wt    PVLVSLTGLGIFRTLSSPLYRRIILGSGPNNQELFVLDGTEFSFASLTTNLPS 
 
A1    PVLVSLTGLGIFRTLSSPLYGARDQGNSGWDSFDYCLFVLDGTEFSFASLTTNLPS 
A2    PVLVSLTGLGIFRTLSSPLYGARDGGPGPPLDCLFVLDGTEFSFASLTTNLPS 
A3    PVLVSLTGLGIFRTLSSPLYGARDVGTLL*QKWSATIACLSLMERSFLLPP*RPTCL 
A4    PVLVSLTGLGIFRTLSSPLYGARDVGTLL*QKWSATIACLSLMERSFLLPP*RPTCL 
A5    PVLVSLTGLGIFRTLSSPLYGAREAWAAAGTLLLISACLSLMERSFLLPP*RPTCL 
A6    PVLVSLTGLGIFRTLSSPLYRRIILGSGPNNQELFVLDGTEFSFASLTTNLPS 
A7    PVLVSLTGLGIFRTLSSPLYRRIILGSGPNNQELFVLDGTEFSFASLTTNLPS 
A8    PVLVSLTGLGIFRTLSSPLYGAREGSSSAYDYWLFVLDGTEFSFASLTTNLPS 
A9    PVLVSLTGLGIFRTLSSPLYGARGLRSSSHFDYCLFVLDGTEFSFASLTTNLPS 
A10   PVLVSLTGLGIFRTLSSPLYGARGQAIFRPAPCWFDPCLFVLDGTEFSFASLTTNLPS 
A11   SVLVSLTGLGIFRTLSSPLYGAREPYGGRAFDIWLFVLDGTEFSFASLTTNLPS 
A12   PVLVSLTGLGIFRTLSSPLYGARGDPDFDHSTSYYLDYCLFVLDGTESSFASLTTNLPS 
A13   PVLVSLTGLGIFRTLSSPLYGARGAPMVRYFDNCLFVLDGTEFSFASLTTNLPS 
A16   PVLVSLTGLGIFRTLSSPLYGARGIFKGRDQAYDYCLFVLDGTEFSFASLTTNLPS 
 
 
 
 
 
A14   PVLVSLTGLGILEHYLHLYMVRGPNWG*TPTTVWTSACLSLMERSFLLPP*RPTCL 
      RTCLINWFGDFRTLSSPLYGARTELGLNSYYGMDVCLFVLDGTEFSFASLTTNLPS 
A15   PVLVSLTGLGIFRTLSSLYMVREMTTLPFLMPACLSLMERSFLLPP*RPTCL  
      RTCLINWFGDF*NIIFTLYGARDDYTTIFDACLFVLDGTEFSFASLTTNLPS 
A2f	 A2r	
Hypervariable	
region	
  40 
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